Security Snapshot

PACER FDS TR - CFRA STVAL EQL (SZNE) Institutional Ownership

CUSIP: 69374H691

13F Institutional Holders and Ownership History from Q3 2018 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

13

Shares (Excl. Options)

171,081

Price

$35.64

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Type / Class
Equity / CFRA STVAL EQL
Symbol
SZNE
Price per share
$38.21
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
171,081
Total reported value
$6,098,113
% of total 13F portfolios
0%
Share change
+24,710
Value change
+$887,980
Number of holders
13
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Key facts

  • SZNE - PACER FDS TR - CFRA STVAL EQL is tracked under CUSIP 69374H691.
  • 13 institutions reported positions in Q1 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 12 to 13 between Q4 2025 and Q1 2026.
  • Reported value moved from $5,108,894 to $6,098,113.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 13 institutions filings for Q1 2026.

Open SEC Evidence

Security key

69374H691

Latest holder period

Q1 2026

13F holders

13

13D/G owners

0

CIK / CUSIP context first

As of 31 Mar 2026, 13 institutional investors reported holding 171,081 shares of PACER FDS TR - CFRA STVAL EQL (SZNE).

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
31
Latest
Q1 2026
Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 171,081 $6,098,113 +$887,980 $35.64 13
2025 Q4 146,371 $5,108,894 -$984,315 $34.90 12
2025 Q3 174,652 $5,961,534 -$4,210,540 $34.14 13
2025 Q2 297,543 $10,257,743 -$2,713,067 $34.47 15
2025 Q1 375,733 $13,058,473 -$5,654,555 $34.75 15
2024 Q4 534,084 $19,587,887 +$959,346 $36.68 20
2024 Q3 510,375 $19,806,995 -$228,821 $39.10 20
2024 Q2 509,271 $18,700,923 -$3,171,383 $36.63 19
2024 Q1 591,481 $23,276,975 +$98,747 $39.51 21
2023 Q4 589,556 $21,367,715 -$5,588,226 $36.37 20
2023 Q3 745,177 $24,112,144 -$3,801,274 $32.40 25
2023 Q2 861,769 $30,722,193 +$1,389,491 $35.64 24
2023 Q1 823,205 $30,482,964 -$794,817 $37.12 26
2022 Q4 845,166 $29,366,445 -$13,845,993 $34.56 26
2022 Q3 1,232,659 $38,305,000 -$934,114 $31.08 23
2022 Q2 1,260,033 $41,900,000 -$4,440,921 $33.24 23
2022 Q1 1,388,261 $51,901,029 -$95,376 $37.15 24
2021 Q4 1,387,223 $55,276,000 +$10,026,560 $39.87 30
2021 Q3 1,336,304 $50,138,000 +$6,951,747 $37.52 25
2021 Q2 1,162,921 $44,202,000 +$1,627,447 $38.02 24
2021 Q1 1,121,240 $39,810,768 -$484,648 $35.51 22
2020 Q4 1,136,157 $36,144,000 -$7,106,990 $31.80 23
2020 Q3 1,361,785 $37,302,000 -$3,958,299 $27.43 23
2020 Q2 1,508,844 $39,112,000 -$1,684,726 $25.93 25
2020 Q1 1,578,083 $34,813,000 +$3,208,144 $22.04 26
2019 Q4 1,392,651 $43,384,000 +$26,765,037 $31.15 24
2019 Q3 587,313 $17,009,000 +$4,769,979 $28.97 14
2019 Q2 422,887 $12,199,000 +$10,304,746 $28.75 9
2019 Q1 65,933 $1,782,000 +$1,561,935 $27.03 7
2018 Q4 8,137 $188,000 -$1,351,010 $23.02 3
2018 Q3 66,449 $1,742,000 +$1,742,000 $26.22 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .